Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/34351
Tipo
ArtículoDerechos de autor
Acceso abierto
Fecha del embargo
2020-07-23
Colecciones
- INI - Artigos de Periódicos [3439]
Metadatos
Mostrar el registro completo del ítem
CHOLINESTERASE INHIBITION REDUCES ARRHYTHMIAS IN ASYMPTOMATIC CHAGAS DISEASE
Arrhythmia
Autonomic diseases
Chagas cardiomyopathy
Cholinesterases
Parasympathetic nervous system
Autor
Afiliación
Fluminense Federal University. Department of Physiology and Pharmacology and Post-Graduate Program in Cardiovascular Sciences. Niterói, RJ, Brazil.
Rio de Janeiro Federal University. Division of Cardiology. Rio de Janeiro, RJ, Brazil.
Rio de Janeiro Federal University. Division of Cardiology. Rio de Janeiro, RJ, Brazil.
Rio Grande do Sul Federal University. Division of Cardiology. Porto Alegre, RS, Brazil.
Rio Grande do Sul Federal University. Division of Cardiology. Porto Alegre, RS, Brazil.
Rio Grande do Sul Federal University. Division of Cardiology. Porto Alegre, RS, Brazil.
Fluminense Federal University. Department of Physiology and Pharmacology and Post-Graduate Program in Cardiovascular Sciences. Niterói, RJ, Brazil.
Rio de Janeiro Federal University. Division of Cardiology. Rio de Janeiro, RJ, Brazil.
Rio de Janeiro Federal University. Division of Cardiology. Rio de Janeiro, RJ, Brazil.
Rio Grande do Sul Federal University. Division of Cardiology. Porto Alegre, RS, Brazil.
Rio Grande do Sul Federal University. Division of Cardiology. Porto Alegre, RS, Brazil.
Rio Grande do Sul Federal University. Division of Cardiology. Porto Alegre, RS, Brazil.
Fluminense Federal University. Department of Physiology and Pharmacology and Post-Graduate Program in Cardiovascular Sciences. Niterói, RJ, Brazil.
Resumen en ingles
Introduction: Parasympathetic dysfunction may play a role in the genesis of arrhyth-mias in Chagas disease. Aim: This study evaluates the acute effects of pyridostigmine (PYR), a reversible cholinest-erase inhibitor, on the occurrence of arrhythmias in patients with Chagas cardiac disease. Method: Following a double-blind, randomized, placebo- controlled, cross- over proto-col, 17 patients (age 50±2 years) with Chagas cardiac disease type B underwent 24- hour Holter recordings after oral administration of either pyridostigmine bromide (45 mg, 3 times/day) or placebo (PLA).Results: Pyridostigmine reduced the 24- hours incidence (median [25%- 75%]) of pre-mature ventricular beats—PLA: 2998 (1920- 4870), PYR: 2359 (940- 3253), P=.044; ventricular couplets—PLA: 84 (15- 159), PYR: 33 (6- 94), P=.046. Although the total number of nonsustained ventricular tachycardia in the entire group was not different (P=.19) between PLA (1 [0- 8]) and PYR (0 [0- 4]), there were fewer episodes under PYR in 72% of the patients presenting this type of arrhythmia (P=.033). Conclusion: Acute administration of pyridostigmine reduced the incidence of nonsus-tained ventricular arrhythmias in patients with Chagas cardiac disease. Further studies that address the use of pyridostigmine by patients with Chagas cardiac disease under a more prolonged follow- up are warranted.
Palabras clave en ingles
Antiarrhythmia drugsArrhythmia
Autonomic diseases
Chagas cardiomyopathy
Cholinesterases
Parasympathetic nervous system
Compartir